American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026

Event · Earnings
Also in this documentGuidance · raise · $200M–$205M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 4, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 3:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AMWL
Bullish
medium confidence
Mentioned
$AMWL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AMWLBullishMed
01

Why it matters

Traders can reprice the stock based on the updated revenue and adjusted EBITDA guidance ranges, plus the stated objective of positive operating cash flow in Q4 2026.

02

Market read

The filing provides fresh, numeric guidance updates (2026 and Q3) and Q2 operating metrics (revenue, gross margin, EBITDA trend) that can drive near-term positioning.

03

What to watch

The filing emphasizes DHA contractor intent and cash-flow timing for Q4, but it also flags risks around client transitions, telehealth demand volatility, and cybersecurity/privacy compliance.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 4, 2026, with Q3 and 2026 guidance ranges

Background

This is an SEC 8-K with Exhibit 99.1 reporting Amwell’s Q2 2026 results and updated financial outlook, including Q3 2026 ranges.

Company-level read

Ticker impact

$AMWLBullishMedium confidence
Context

Amwell reported Q2 2026 revenue of $52.0M, gross margin of 53%, and raised the low end of 2026 revenue and adjusted EBITDA guidance.

Expected impact

Near-term bias upward on guidance credibility, with volatility risk given continued GAAP net losses and non-GAAP framing.

Evidence & confidence

The filing includes specific Q2 results and updated 2026 and Q3 ranges, which are actionable for positioning. However, the company does not reconcile forward-looking adjusted EBITDA to GAAP, and GAAP net loss persists, limiting conviction.

Market effects

Reinforces a potential inflection narrative for telehealth/SaaS healthcare platforms via subscription growth and improving EBITDA trajectory.

No specific regional spillover disclosed beyond US healthcare contracting.

Limited, as the disclosed guidance and DHA relationship are US-focused.

Counterpoint

Non-GAAP adjusted EBITDA remains negative and GAAP net loss is still sizable, so the guidance raise may not translate into durable profitability.

Key entities

  • American Well Corp

    NYSE-listed SaaS-based healthcare platform provider reporting Q2 2026 results and updated guidance.

  • Defense Health Agency (DHA)

    Referenced as intending to make Amwell a prime contractor, supporting the platform endorsement narrative.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.